Combination Antiplatelet Therapy in Patients with Peripheral Vascular Bypass Grafts

Clinical and Applied Thrombosis/Hemostasis

Volumn 10, Issue 1, 2004, Pages 9-18

  Smout, Jonathan D ^a,b   Mikhailidis, Dimitri P ^c   Shenton, Brian K ^b   Stansby, Gerard ^a,b  

^a FREEMAN HOSPITAL   (United Kingdom)

^b NEWCASTLE UNIVERSITY   (United Kingdom)

^c ROYAL FREE HOSPITAL   (United Kingdom)

Author keywords

Aspirin; Clopidogrel; Peripheral bypass; Platelet

Indexed keywords

ACETYLSALICYLIC ACID; ADENOSINE DIPHOSPHATE; ANTITHROMBOCYTIC AGENT; ARACHIDONIC ACID; CLOPIDOGREL; FIBRINOGEN RECEPTOR; PADGEM PROTEIN;

ADULT; AGED; ANTICOAGULATION; ARTICLE; BLOOD VESSEL SHUNT; BYPASS SURGERY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; EX VIVO STUDY; FEMALE; FLOW CYTOMETRY; GRAFT OCCLUSION; HUMAN; INGUINAL REGION; MALE; PERIPHERAL VASCULAR DISEASE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION; THROMBOSIS;

EID: 2142660111     PISSN: 10760296     EISSN: None     Source Type: Journal    
DOI: 10.1177/107602960401000103     Document Type: Article

References (34)

1. Sayers RD, Thompson MM, Hartshorne T, Budd JS, Bell PR. Treatment and outcome of severe lower-limb ischaemia. Br J Surg 1994;81:521.
2. Begramini T, Towne J, Bandyke D, et al. Experience with in-situ vein bypasses during 1981 to 1989: Determinant factors on long-term patency. J Vasc Surg 1991;13:137.
3. Antithrombotic Trialist' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for the prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002;324:71.
4. Robless P, Mikhailidis DP, Stansby G. Systematic review of antiplatelet therapy for the prevention of myocardial infarction, stroke or vascular death in patients with peripheral vascular disease. Br J Surg 2001;88:787.
5. Tangelder M, Lawson J, Algra A, Eikelboom B. Systematic review of randomised controlled trials of aspirin and oral anticoagulants in the prevention of graft occlusion and ischaemic events after infrainguinal bypass surgery. J Vasc Surg 1999;30:701.
6. Becquemin JP. Effect of ticlopidine on the long-term patency of saphenous-vein bypass grafts in the legs. Etude de la Ticlopidine apres Pontage Femoro-Poplite and the Association Universitaire de Recherche en Chirurgie. N Engl J Med 1997;337:1726.
7. Robless PA, Okonko D, Lintott P, Mansfield AO, Mikhailidis DP, Stansby GP. Increased platelet aggregation and activation in peripheral arterial disease. Eur J Vasc Endovasc Surg 2003;25:16.
8. The Clopidogrel in Unstable angina to prevent Recurrent Events investigators. Effects of clopidogrel in addition to aspirin in patents with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001;345:494.
9. Diener HC, Cunha L, Forbes C, Sivenius J, Smets P, Lowenthal A. European Stroke Prevention Study. 2. Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke. J Neurol Sci 1996;143:1.
10. Gran A, Reiners S, Lichy C, Buggle F, Ruf A. Platelet function under aspirin, clopidogrel, and both after ischaemic stroke: A case-crossover study. Stroke 2003;43:849.
11. Dorr G, Schmidt G, Grafe M, Regitz-Zagrosek V, Fleck E. Effects of combined therapy with clopidogrel and acetyl-salicylic acid on platelet glycoprotein expression and aggregation. J Cardiovasc Pharmacol. 2002;39:523.
12. Barradas M, O'Donoghue S, Mikhailidis D. Advantages of whole blood platelet aggregation measured by a cell counter (Coulter T-890) in drug evaluation. J Drug Dev 1992;5:155.
13. Robless P, Tegos T, Okonko D, Mansfield A, Nicolaides A, Mikhailidis D, Stansby G. Platelet Activation During Carotid Endarterectomy And the Antiplatelet effect of Dextran 40. Platelets 2002;13:231.
14. Schmitz G, Rothe G, Ruf A, Barlage S, Tschope D, Clemetson KJ, Goodall AH, Michelson AD, Nurden AT, Shankey TV. European Working Group on Clinical Cell Analysis: Consensus protocol for the flow cytometric characterisation of platelet function. Thromb Haemost 1998;79:885.
15. Shattil SJ, Cunningham M, Hoxie JA. Detection of activated platelets in whole blood using activation-dependent monoclonal antibodies and flow cytometry. Blood 1987;70:307.
16. Mallet S. Thrombelastography. Br J Anaesth 1992;69:307.
17. Bowbrick V, Mikhailidis D, Stansby G. The value of thrombelastography in the assessment of platelet function. Clin Appl Thromb Hemost. In press.
18. Harker L, Marzec U, Kelly A, Chronos N, Sundell I, Hanson S, Herbert J. Clopidogrel inhibition of stent, graft, and vascular thrombogenesis with antithrombotic enhancement by aspirin in nonhuman primates. Circulation 1998;98:2461.
19. Payne D, Hayes P, Jones C, Belham P, Naylor A, Goodall A. Combined therapy with clopidogrel and aspirin significantly increases bleeding time through synergistic antiplatelet action. J Vasc Surg 2002;35:1204.
20. Eikelboom JW, Hirsh J, Weitz JI, Johnston M, Yi Q, Yusuf S. Aspirin-resistant thromboxane biosynthesis and the risk of myocardial infarction, stroke, or cardiovascular death in patients at high risk for cardiovascular events. Circulation 2002;105:1650.
21. Orford JL, Selwyn AP, Ganz P, Popma JJ, Rogers C. The comparative pathobiology of atherosclerosis and restenosis. Am J Cardiol 2000;86:6H.
22. Ross R. Atherosclerosis: Current understanding of mechanisms and future strategies in therapy. Transplant Proc 1993;25:2041.
23. Chandrasekar B TJ. Platelets and restenosis. J Am Coll Cardiol 2000;35:555.
24. Barradas MA, Jagroop IA, Mikhailidis DP. Naftidrofuryl inhibits the release of 5-hydroxytryptamine and platelet-derived growth factor from human platelets. Clin Chim Acta 1994;230:157.
25. Cheshire NJ, Wolfe JH, Barradas MA, Chambler AW, Mikhailidis DP. Smoking and plasma fibrinogen, lipoprotein (a) and serotonin are markers for postoperative infrainguinal graft stenosis. Eur J Vasc Endovasc Surg 1996; 11:479.
26. Patel KD, Moore KL, Nollert MU, MeEver RP. Neutrophils use both shared and distinct mechanisms to adhere to selectins under static and flow conditions. J Clin Invest. 1995;96:1887.
27. 12 receptor as a therapeutic target in cardiovascular disease. Platelets 2001;12:197.
28. Malik I, Danesh J, Whincup P, Bhatia V, Papacosta O, Walker M, Lennon L, Thomson A, Haskard D. Soluble adhesion molecules and prediction of coronary heart disease: A prospective study and metaanalysis. Lancet 2001;358:971.
29. Ridker PM, Buring JE, Rifai N. Soluble P-selectin and the risk of future cardiovascular events. Circulation 2001; 103:491.
30. Seyfarth HJ, Koksch M, Roethig G, Rother T, Neugebauer A, Klein N, Pfeiffer D. Effect of 300- and 450-mg clopidogrel loading doses on membrane and soluble P-selectin in patients undergoing coronary stent implantation. Am Heart J 2002;143:118.
31. Blann A, Seigneur M, Boisseau M, Taberner D, McCollum C. Soluble P selectin in peripheral vascular disease: Relationship to the location and extent of atherosclerotic disease and its risk factors. Blood Coag Fibrinolysis 1996;7:798.
32. Lip G, Blann A, Farooqi I, Zarifis J, Sagar G, Beevers D. Sequential alteration in haemorheology, endothelial dysfunction, platelet activation and thrombogenesis in relation to prognosis following acute stroke: The West Birmingham Stroke Project. Blood Coag Fibrinolysis 2002;13:339.
33. Hillis G, Terregino C, Taggart P, Killian A, Zhao N, WC. D, Mangione A. Elevated soluble P-selectin levels are associated with an increased risk of early adverse events in patients with presumed myocardial ischemia. Am Heart J 2002;143:235.
34. Hongo RH, Ley J, Dick SE, Yee RR. The effect of clopidogrel in combination with aspirin when given before coronary artery bypass grafting. J Am Coll Cardiol 2002; 40:231.